Europe Palmoplantar Pustulosis Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2020
  • Europe
  • 350 Pages
  • No of Tables: 292
  • No of Figures: 46

Europe Palmoplantar Pustulosis (PPP) Market, By Disease Type (Type A, Type B), Severity (Mild Moderate, Moderate Severe), Type (Diagnosis, Treatment), Population Type (Children, Adults), Route of Administration (Oral, Topical, Parenteral), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Home Healthcare), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Hungary, Ireland, Poland, and Rest of Europe) Industry Trends and Forecast to 2027  

Europe Palmoplantar Pustulosis Market

Europe Market Analysis and Insights: Europe Palmoplantar Pustulosis Market

Palmoplantar pustulosis (PPP) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.5% in the forecast period of 2020 to 2027 and is expected to reach USD 126.60 million by 2027 from USD 91.17 million in 2019. Increasing prevalence of palmoplantor pustulosis and increasing number of smokers are the major drivers which propelled the demand of the market in the forecast period.

Palmoplantar pustulosis is one of the autoinflammatory diseases, the exact cause of which is still unknown. This has been reported that it is the form of psoriasis and approximately 24 percent of patients have psoriasis on their body. As per the several studies conducted, smoking is one of the precipitating factors responsible for the development of palmoplantar pustulosis, however, some other factors are also related to PPP development which includes metal sensitivities, trauma, stress, infections among others. Among the different sex, women have been reported to affect more.

Moreover, heredity factors also plays role in PPP development. As per the studies conducted, people having autoimmune disorders such as arthritis, thyroid disorders, coeliac disease, and diabetes among others are more prone to palmoplantar pustulosis. People suffering from palmoplantar pustulosis develops tiny blisters filled with the white/yellow liquid and became scaly. The several diagnostic tests used for identifying the disease symptoms involve skin biopsy and skin tests among others.

The demand for palmoplantar pustulosis (PPP) has been increased in both developing as well as in developed countries and the reason behind this is an rise in cases of metal allergies, increasing women population, increase in the number of smokers, presence of diversified treatment options. The palmoplantar pustulosis (PPP) market is growing due to an increase in research and developmental activities, presence of drugs under clinical trials, an increasing number of biologic drug approvals for PPP. The market will grow in the forecasted period with rising disposable income among other favourable factors. However, lack of diagnosis, high cost of treatment among other factors is expected to restrain the Europe palmoplantar pustulosis (PPP) market growth.

The palmoplantar pustulosis (PPP) report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Palmoplantar Pustulosis Market

Europe Palmoplantar Pustulosis (PPP) Market Scope and Market Size

Palmoplantar pustulosis (PPP) market is segmented into seven notable segments which are disease type, severity, type, population type, route of administration, end user and distribution channel.

  • On the basis of disease type, Europe palmoplantar pustulosis (PPP) market is segmented into type A, and type B. In 2020, type B is dominating the market as it is one of the most reportable form of palmoplantar pustulosis and patients who have different forms of psoriasis usually develops palmoplantar pustulosis.
  • On the basis of severity, Europe palmoplantar pustulosis (PPP) market is segmented into mild-moderate, and moderate-severe. In 2020, moderate-severe is dominating the market because large population size diagnosed with such type of palmoplantar pustulosis due to increasing prevalence of psoriasis.
  • On the basis of type, Europe palmoplantar pustulosis (PPP) market is segmented into diagnosis, and treatment. In 2020, diagnosis segment is dominating the market because patient suffering from PPP frequently misdiagnosed due to presence of different kinds of symptoms associated with this disease which puts the great need of multiple time diagnosis.
  • On the basis of population type, Europe palmoplantar pustulosis (PPP) market is segmented into children and adults. In 2020, adults segment is dominating as is less prevalent in children and most of the studies conducted demonstrated that it affects individuals at the age of 30-50 years of age.
  • On the basis of route of administration, Europe palmoplantar pustulosis (PPP) market is segmented into oral, topical, parenteral. In 2020, parenteral is dominating because parenteral formulations directly reaches to systemic circulation and have higher efficacy rate as compared to other route of drug administration. Moreover biological therapies indicated for PPP treatment are available in injectable formulation.
  • On the basis of end user, Europe palmoplantar pustulosis (PPP) market is segmented into hospitals, specialty clinics, diagnostic centers, home healthcare. In 2020, diagnostic centers are dominating as the PPP prevalence is increasing it enhances the diagnostic rate because most of the misdiagnosed cases.
  • On the basis of distribution channel, Europe palmoplantar pustulosis (PPP) market is segmented into direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. In 2020, hospital pharmacies is dominating the market as the patients suffering from PPP frequently visits hospital in order to achieve accurate treatment where they procures drugs form the nearby hospital pharmacies.

Palmoplantar Pustulosis Market Country Level Analysis

The palmoplantar pustulosis market is analysed and market size information is provided disease type, severity, type, population type, route of administration, end user and distribution channel.

The countries Europe covered in the palmoplantar pustulosis market report are the Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Hungary, Ireland, Poland, and Rest of Europe.

Germany is expected to grow with the highest CAGR in the forecast period as rising skin related disorders and increasing population with smoking habits across European countries. Germany is expected to dominate the Europe market because Germany is one of the leading countries for the technological advancement. The U.K. holds the second highest market share due to increased population with chronic skin diseases and increasing population with smoking habits. Italy is growing with healthy CAGR because of growing population with unhealthy lifestyle in the country.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Palmoplantar Pustulosis Market 

Palmoplantar pustulosis (PPP) market also provides you with detailed market analysis for every country growth in palmoplantar pustulosis sales, impact of advancement in the palmoplantar pustulosis and changes in regulatory scenarios with their support for the palmoplantar pustulosis (PPP) market. The data is available for historic period 2010 to 2018.  

Competitive Landscape and Palmoplantar Pustulosis (PPP) Market Share Analysis

Palmoplantar pustulosis (PPP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to palmoplantar pustulosis (PPP) market.

The major players covered in the report are Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Pharmaceuticals, Inc.  (A Subsidiary of Johnson & Johnson Services, Inc.), AbbVie Inc., Bristol-Myers Squibb Company, Perrigo Company plc, F. Hoffmann-La Roche Ltd, WOCKHARDT, Teligent, Bausch Health Companies Inc., Mylan N.V., The Daavlin Company, GlaxoSmithKline plc., Amneal Pharmaceuticals LLC., Xiromed among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the palmoplantar pustulosis (PPP) market.

For instance,  

  • In November 2018, F. Hoffmann-La Roche Ltd received approval for ACTPen, a device used for accurate delivery of Actemra ((tocilizumab) a biological therapy used for treatment of inflammatory symptoms associated with palmoplantar pustulosis (PPP). This approval allowed the patients and physicians to monitor the accurate drug dosage. This approval thus allowed the company to earn more revenue.
  • In April 2018, Teligent received FDA approval for Clobetasol Propionate Cream USP, 0.05%, a formulation indicated for treatment of inflammatory symptoms associated with palmoplantar pustulosis (PPP). The availability of different dosage form enhanced the company’s product portfolio and also boosted the company revenue.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the palmoplantar pustulosis market which also provides the benefit for organisation to improve their offering for palmoplantar pustulosis.   

Customization Available: Europe Palmoplantar Pustulosis Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, PIPELINE ANALYSIS

TABLE 2 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 3 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE TYPE B PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE TYPE A PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY SEVERITY,2019-2027 (USD MILLION)

TABLE 6 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE MODERATE TO SEVER PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE MILD TO MODERATE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 9 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE DIAGNOSIS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 10 U.S., EUROPE, CHINA & JAPAN DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPETREATMENT PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 12 U.S., EUROPE, CHINA & JAPAN TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 13 U.S., EUROPE, CHINA & JAPAN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 14 U.S., EUROPE, CHINA & JAPAN IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 15 U.S., EUROPE, CHINA & JAPAN TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 16 U.S., EUROPE, CHINA & JAPAN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 17 U.S., EUROPE, CHINA & JAPANTOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 18 U.S., EUROPE, CHINA & JAPAN SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 19 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY POPULATION TYPE ,2019-2027 (USD MILLION)

TABLE 20 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE ADULTS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE ADULTS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 22 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 23 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 24 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 25 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 26 U.S., EUROPE, CHINA & JAPAN TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 27 U.S., EUROPE, CHINA & JAPAN ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 28 U.S., EUROPE, CHINA & JAPAN TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 29 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 30 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE DIAGNOSTIC CENTERS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 31 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE SPECIALTY CLINICS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE HOSPITALS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE HOME HEALTHCARE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 35 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE HOSPITAL PHARMACIES PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 36 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE RETAIL PHARMACIES PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE DIRECT TENDERS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 39 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 40 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 41 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 42 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 43 EUROPE DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 44 EUROPE TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 45 EUROPE BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 46 EUROPE IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 47 EUROPE TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 48 EUROPE TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 49 EUROPE TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 EUROPE SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 52 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 53 EUROPE PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 54 EUROPE TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 EUROPE ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 56 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 EUROPE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 59 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 60 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 GERMANY DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 GERMANY TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 63 GERMANY BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 GERMANY IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 65 GERMANY TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 66 GERMANY TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 67 GERMANY TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 68 GERMANY SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 69 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 70 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 71 GERMANY PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 72 GERMANY TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 73 GERMANY ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 74 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 75 GERMANY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 76 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 77 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 78 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 79 U.K. DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 U.K. TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 U.K. BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 82 U.K. IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 83 U.K. TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 84 U.K. TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 85 U.K. TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 86 U.K. SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 87 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 88 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 89 U.K. PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 90 U.K. TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 91 U.K. ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 92 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 93 U.K. PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 94 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 95 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 96 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 97 ITALY DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 98 ITALY TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 99 ITALY BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 ITALY IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 ITALY TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 102 ITALY TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 103 ITALY TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 104 ITALY SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 105 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 106 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 107 ITALY PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 108 ITALY TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 109 ITALY ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 110 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 111 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 112 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 113 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 114 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 115 ITALY DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 116 ITALY TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 117 ITALY BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 118 ITALY IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 119 ITALY TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 ITALY TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 121 ITALY TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 122 ITALY SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 123 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 124 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 125 ITALY PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 126 ITALY TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 127 ITALY ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 128 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 129 ITALY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 130 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 132 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 133 SPAIN DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 134 SPAIN TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 135 SPAIN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 136 SPAIN IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 137 SPAIN TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 138 SPAIN TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 139 SPAIN TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 SPAIN SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 142 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 143 SPAIN PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 144 SPAIN TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 145 SPAIN ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 146 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 147 SPAIN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 148 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 149 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 150 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 151 NETHERLANDS DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 152 NETHERLANDS TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 153 NETHERLANDS BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 154 NETHERLANDS IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 155 NETHERLANDS TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 156 NETHERLANDS TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 157 NETHERLANDS TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 158 NETHERLANDS SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 159 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 160 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 161 NETHERLANDS PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 162 NETHERLANDS TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 163 NETHERLANDS ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 164 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 165 NETHERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 166 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 167 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 168 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 169 RUSSIA DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 170 RUSSIA TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 171 RUSSIA BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 172 RUSSIA IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 173 RUSSIA TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 174 RUSSIA TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 175 RUSSIA TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 176 RUSSIA SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 177 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 178 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 179 RUSSIA PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 180 RUSSIA TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 181 RUSSIA ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 182 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 183 RUSSIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 184 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 185 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 186 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 187 SWITZERLANDS DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 188 SWITZERLANDS TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 189 SWITZERLANDS BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 190 SWITZERLANDS IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 191 SWITZERLANDS TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 192 SWITZERLANDS TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 193 SWITZERLANDS TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 194 SWITZERLANDS SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 195 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 196 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 197 SWITZERLANDS PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 198 SWITZERLANDS TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 199 SWITZERLANDS ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 200 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 201 SWITZERLANDS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 202 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 203 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 204 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 205 TURKEY DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 206 TURKEY TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 207 TURKEY BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 208 TURKEY IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 209 TURKEY TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 210 TURKEY TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 211 TURKEY TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 212 TURKEY SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 213 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 214 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 215 TURKEY PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 216 TURKEY TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 217 TURKEY ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 218 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 219 TURKEY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 220 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 221 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 222 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 223 AUSTRIA DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 224 AUSTRIA TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 225 AUSTRIA BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 226 AUSTRIA IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 227 AUSTRIA TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 228 AUSTRIA TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 229 AUSTRIA TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 230 AUSTRIA SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 231 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 232 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 233 AUSTRIA PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 234 AUSTRIA TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 235 AUSTRIA ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 236 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 237 AUSTRIA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 238 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 239 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 240 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 241 HUNGARY DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 242 HUNGARY TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 243 HUNGARY BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 244 HUNGARY IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 245 HUNGARY TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 246 HUNGARY TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 247 HUNGARY TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 248 HUNGARY SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 249 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 250 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 251 HUNGARY PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 252 HUNGARY TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 253 HUNGARY ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 254 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 255 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 256 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 257 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY, 2018-2027 (USD MILLION)

TABLE 258 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 259 IRELAND DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 260 IRELAND TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 261 IRELAND BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 262 IRELAND IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 263 IRELAND TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 264 IRELAND TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 265 IRELAND TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 266 IRELAND SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 267 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 268 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 269 IRELAND PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 270 IRELAND TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 271 IRELAND ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 272 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 273 IRELAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 274 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISEASE TYPE 2018-2027 (USD MILLION)

TABLE 275 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY 2018-2027 (USD MILLION)

TABLE 276 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 277 POLAND DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 278 POLAND TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 279 POLAND BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 280 POLAND IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 281 POLAND TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 282 POLAND TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 283 POLAND TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 284 POLAND SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 285 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE 2018-2027 (USD MILLION)

TABLE 286 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 287 POLAND PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 288 POLAND TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 289 POLAND ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 290 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 291 POLAND PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 292 HUNGARY PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions